根据最新的SEC文件显示，Avidity Biosciences, Inc.（NASDAQ:RNA）的首席科学官Flanagan W.

Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

Avidity Biosciences, ...

BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to ...

Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...

2025年3月3日，市值34亿美元的Avidity Biosciences, Inc.（NASDAQ:RNA）首席项目官Kathleen P.

利用人体等效生物活性蛋白改变营养状况的生物技术公司Helaina近日宣布，公司已获得4500万美元的B轮融资，使公司的股权融资总额达到8300万美元。本轮融资由 Avidity Partners 领投，Spark Capital、Ingeborg ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is ...

Avidity Biosciences, Inc. (NASDAQ:RNA) has emerged as a frontrunner in the development of RNA-based therapies, leveraging its proprietary antibody-oligonucleotide conjugate (AOC) platform to ...

Avidity Sponsored Industry Forum Breakfast Event During MDA Conference SOURCE Avidity Biosciences, Inc. The views and opinions expressed herein are the views and opinions of the author and do not ...